Effects of the combination therapy of hemodialysis with hemoperfusion on medium molecular toxins and protein bound uremic toxins in maintenance hemodialysis patients.
Combining hemodialysis with hemoperfusion significantly reduces certain toxins in dialysis patients, but further research is needed to confirm optimal treatment frequency.
Where it sits
this study against the rest of the zenagamtide corpusSummary and findings
This single-center observational study evaluated the effect of combining hemodialysis with hemoperfusion on medium molecular toxins and protein-bound uremic toxins in 38 maintenance hemodialysis patients over 12 weeks. Significant reductions in serum β2-microglobulin, indoxyl sulfate, and p-cresyl sulfate levels were observed. No significant difference in reduction ratios was found between patients receiving more or fewer hemoperfusion sessions.
Abstract
<h4>Introduction</h4>This study aimed to observe the reduction rations of the combination therapy of HD with hemoperfusion(HP) on medium molecular toxins and PBUTs in MHD patients.<h4>Methods</h4>In this single-center observational study, 38 MHD patients were treated with HD plus HP using the Jafron KHA130 cartridge for 12 weeks. Serum concentrations of β2-microglobulin (β2-MG), indoxyl sulfate (IS), and p-cresyl sulfate (PCS) were measured by Enzyme-Linked Immunosorbent Assay (ELISA) at baseline and after 12 weeks, and their reduction rates were calculated. Patients were stratified by the number of HP sessions received during the study period: Group A (>4 times/12 weeks, n=16) and Group B (≤4 times/12 weeks, n=22). The reduction ratio of blood β2-MG and PBUTs(PCS, IS) from baseline were compared between the two groups of patients at 12 weeks.<h4>Results</h4>After the 12-week study period, significant reductions were observed in serum levels of β2-MG (from 29.72±5.61 to 21.50±6.69 μg/ml, t=5.882, P<0.001; median reduction ratio 30.48%), IS (from 14.04±1.70 to 11.70±1.12 μg/ml, t=7.199, P<0.001; median reduction ratio 14.61%), and PCS (from 8.09±1.58 to 6.63±1.33 μg/ml, t=4.984, P<0.001; median reduction ratio 17.10%). There was no statistically significant difference in the reduction ratio of β2-MG, PCS and IS between Group A and Group B (P>0.05). The treatment was well tolerated, with only three episodes of hypotension that resolved with conservative management.<h4>Conclusion</h4>Combined HD and HP therapy was associated with lower serum levels of β2-MG, IS, and PCS in MHD patients, suggesting this modality may represent a viable strategy for achieving reductions in PBUT and medium molecular toxin levels. The relationship between HP session frequency and toxin reduction requires further investigation in adequately powered randomized controlled trials.
Background
The study addresses the challenge of reducing medium molecular toxins and protein-bound uremic toxins in maintenance hemodialysis patients. These toxins are difficult to remove and contribute to complications in dialysis patients. Previous studies have suggested potential benefits of combining hemodialysis with hemoperfusion, but concrete evidence in this specific patient population is limited.
Methods
This was a single-center observational study involving 38 maintenance hemodialysis patients. Participants received hemodialysis combined with hemoperfusion using the Jafron KHA130 cartridge over 12 weeks. Serum levels of β2-microglobulin, indoxyl sulfate, and p-cresyl sulfate were measured at baseline and after 12 weeks using ELISA. Patients were divided into two groups based on the frequency of hemoperfusion sessions: Group A (>4 times/12 weeks) and Group B (≤4 times/12 weeks).
Results
Significant reductions in serum β2-microglobulin (from 29.72±5.61 to 21.50±6.69 μg/ml), indoxyl sulfate (from 14.04±1.70 to 11.70±1.12 μg/ml), and p-cresyl sulfate (from 8.09±1.58 to 6.63±1.33 μg/ml) were observed after 12 weeks, with P<0.001 for all. The median reduction ratios were 30.48% for β2-microglobulin, 14.61% for indoxyl sulfate, and 17.10% for p-cresyl sulfate. No significant differences were found in reduction ratios between the two groups based on hemoperfusion frequency.
Interpretation
The study demonstrates statistically significant reductions in key toxins, suggesting potential benefits of combined hemodialysis and hemoperfusion. However, the lack of significant differences between groups with varying session frequencies indicates that further research is needed to optimize treatment protocols. The clinical significance of these reductions remains uncertain, and the findings should be interpreted cautiously due to the study's limitations.
Key findings
- β2-MG reduced from 29.72±5.61 to 21.50±6.69 μg/ml, t=5.882, P<0.001
- IS reduced from 14.04±1.70 to 11.70±1.12 μg/ml, t=7.199, P<0.001
- PCS reduced from 8.09±1.58 to 6.63±1.33 μg/ml, t=4.984, P<0.001
- Median reduction ratio for β2-MG was 30.48%
- No significant difference in toxin reduction between Group A and Group B (P>0.05)
Limitations
- small n=38
- single-center study
- observational design
- no control group
- short 12-week duration